{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:51:05Z","timestamp":1790470265895,"version":"4.1.0"},"reference-count":22,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2014,12,30]],"date-time":"2014-12-30T00:00:00Z","timestamp":1419897600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2015,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:label\/><jats:p>The induction of CYP2C9 by dabrafenib using S\u2010warfarin as a probe and the effects of a CYP3A inhibitor (ketoconazole) and a CYP2C8 inhibitor (gemfibrozil) on dabrafenib pharmacokinetics were evaluated in patients with BRAF V600 mutation\u2010positive tumors. Dabrafenib single\u2010 and repeat\u2010dose pharmacokinetics were also evaluated. S\u2010warfarin AUC<jats:sub>0\u2013<\/jats:sub><jats:sub>\u221e<\/jats:sub> decreased 37% and C<jats:sub>max<\/jats:sub> increased 18% with dabrafenib. Dabrafenib AUC<jats:sub>0\u2013<\/jats:sub><jats:sub>\u03c4<\/jats:sub> and C<jats:sub>max<\/jats:sub> increased 71% and 33%, respectively, with ketoconazole. Hydroxy\u2010 and desmethyl\u2010dabrafenib AUC<jats:sub>0\u2013\u03c4<\/jats:sub> increased 82% and 68%, respectively, and AUC for carboxy\u2010dabrafenib decreased 16%. Dabrafenib AUC<jats:sub>0\u2013\u03c4<\/jats:sub> increased 47%, with no change in C<jats:sub>max<\/jats:sub>, after gemfibrozil co\u2010administration. Gemfibrozil did not affect systemic exposure to dabrafenib metabolites. Single\u2010 and repeat\u2010dose dabrafenib pharmacokinetics were consistent with previous reports. All cohorts used the commercial capsules. More\u2010frequent monitoring of international normalized ratios is recommended in patients receiving warfarin during initiation or discontinuation of dabrafenib. Substitution of strong inhibitors or strong inducers of CYP3A or CYP2C8 is recommended during treatment with dabrafenib.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jcph.437","type":"journal-article","created":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T09:07:02Z","timestamp":1417424822000},"page":"392-400","source":"Crossref","is-referenced-by-count":45,"title":["Assessment of the drug interaction potential and single\u2010 and repeat\u2010dose pharmacokinetics of the BRAF inhibitor dabrafenib"],"prefix":"10.1002","volume":"55","author":[{"given":"A. Benjamin","family":"Suttle","sequence":"first","affiliation":[{"name":"GlaxoSmithKline Research Triangle Park NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth F.","family":"Grossmann","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute University of Utah Salt Lake City UT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Ouellet","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Research Triangle Park NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren E.","family":"Richards\u2010Peterson","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Collegeville PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gursel","family":"Aktan","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Collegeville PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Gordon","sequence":"additional","affiliation":[{"name":"Pinnacle Oncology Hematology Scottsdale AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia M.","family":"LoRusso","sequence":"additional","affiliation":[{"name":"Karmanos Cancer Institute Wayne State University Detroit MI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Infante","sequence":"additional","affiliation":[{"name":"Sarah Cannon Research Institute\/Tennessee Oncology PLLC Nashville TN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Sharma","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute University of Utah Salt Lake City UT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Kendra","sequence":"additional","affiliation":[{"name":"Ohio State University Columbus OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Patel","sequence":"additional","affiliation":[{"name":"Sarah Cannon Research Institute\/Florida Cancer Specialists Sarasota FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubham","family":"Pant","sequence":"additional","affiliation":[{"name":"Sarah Cannon Research Institute\/University of Oklahoma Oklahoma City OK USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik\u2010Tobias","family":"Arkenau","sequence":"additional","affiliation":[{"name":"Sarah Cannon Research Institute, United Kingdom and University College London London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Middleton","sequence":"additional","affiliation":[{"name":"Department of Oncology National Institute for Health Research Biomedical Research Centre Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel C.","family":"Blackman","sequence":"additional","affiliation":[{"name":"Juno Therapeutics, Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Botbyl","sequence":"additional","affiliation":[{"name":"Provonix LLC Mullica Hill NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley W.","family":"Carson","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Research Triangle Park NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,12,30]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0067583"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60398-5"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.263"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.113.053785"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.114.057778"},{"key":"e_1_2_8_7_1","unstructured":"2014 GlaxoSmithKline Research Triangle Park NC"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.105.013169"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.62.3.737"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.103.058818"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.64.2.316"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.62.3.638"},{"key":"e_1_2_8_13_1","volume-title":"Draft Guidance on Drug Interaction Studies\u2014Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations","year":"2012"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.23519"},{"key":"e_1_2_8_15_1","unstructured":"2010 National Cancer Institute Bethesda MD"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2009.04.002"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(96)90018-1"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1987.168"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198611060-00005"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1994.60"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.73"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-003-1034-7"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60868-X"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcph.437","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.437","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T14:08:35Z","timestamp":1696342115000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,30]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.1002\/jcph.437"],"URL":"https:\/\/doi.org\/10.1002\/jcph.437","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,30]]}}}